Sweden's IRLAB Q4 net sales fall sharply yr/yr

IRLAB Therapeutics AB

25/02/2026 06:07

Overview

Sweden's Parkinson's treatment developer's Q4 net sales fell significantly yr/yr

Company's Q4 operating profit decreased compared to previous year

Company entered collaboration with Biomia ApS for drug candidate evaluation

Outlook

IRLAB advancing Phase Ib study for IRL757 in Parkinson's disease

Company strengthens patent protection for mesdopetam, enhancing market potential

IRLAB collaborates with Biomia to evaluate drug candidates using its research platform

Result Drivers

IRL757 STUDY ADVANCEMENT - IRLAB advanced the study of IRL757 in Parkinson's disease, supported by a USD 4 million payment from partner MSRD

REGULATORY APPROVALS - IRLAB received regulatory and ethical approvals for a Phase Ib study of IRL757, progressing its clinical development

PATENT STRENGTHENING - IRLAB strengthened its patent portfolio for mesdopetam, enhancing its commercial potential

Company press release: ID:nMFN6CfHGf

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
SEK 14.70 mln
Q4 Adjusted EPS
-SEK 0.29
Q4 EBIT
-SEK 21.90 mln
Q4 Operating Cash Flow
-SEK 26 mln


Analyst Coverage

Wall Street's median 12-month price target for IRLAB Therapeutics AB is SEK12.00, about 657.6% above its February 24 closing price of SEK1.58

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)